HK1139860A1 - Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome - Google Patents

Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome

Info

Publication number
HK1139860A1
HK1139860A1 HK10106298.4A HK10106298A HK1139860A1 HK 1139860 A1 HK1139860 A1 HK 1139860A1 HK 10106298 A HK10106298 A HK 10106298A HK 1139860 A1 HK1139860 A1 HK 1139860A1
Authority
HK
Hong Kong
Prior art keywords
kappa
diarrhea
predominant
treatment
bowel syndrome
Prior art date
Application number
HK10106298.4A
Other languages
English (en)
Inventor
Allen Mangel
Original Assignee
Tioga Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tioga Pharmaceuticals Inc filed Critical Tioga Pharmaceuticals Inc
Publication of HK1139860A1 publication Critical patent/HK1139860A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
HK10106298.4A 2007-03-30 2010-06-28 Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome HK1139860A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92084107P 2007-03-30 2007-03-30
PCT/US2008/056317 WO2008121496A1 (en) 2007-03-30 2008-03-07 Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome

Publications (1)

Publication Number Publication Date
HK1139860A1 true HK1139860A1 (en) 2010-09-30

Family

ID=39795494

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10106298.4A HK1139860A1 (en) 2007-03-30 2010-06-28 Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome

Country Status (20)

Country Link
US (2) US7960429B2 (xx)
EP (3) EP2636407A3 (xx)
JP (2) JP5416085B2 (xx)
KR (2) KR101208326B1 (xx)
CN (2) CN101677997B (xx)
AU (1) AU2008232954A1 (xx)
BR (1) BRPI0809651A2 (xx)
CA (1) CA2682608A1 (xx)
CY (1) CY1113317T1 (xx)
DK (1) DK2136801T3 (xx)
ES (1) ES2393815T3 (xx)
HK (1) HK1139860A1 (xx)
HR (1) HRP20120798T1 (xx)
IL (1) IL201226A0 (xx)
MX (1) MX2009010409A (xx)
PL (1) PL2136801T3 (xx)
PT (1) PT2136801E (xx)
RU (1) RU2441655C2 (xx)
SI (1) SI2136801T1 (xx)
WO (1) WO2008121496A1 (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5416085B2 (ja) * 2007-03-30 2014-02-12 ティオガ ファーマシューティカルズ インコーポレイテッド 下痢型および交替型過敏性腸症候群の処置のためのカッパ−オピエートアゴニスト
US9303027B2 (en) 2010-07-19 2016-04-05 Dr. Reddy's Laboratories Ltd. Kappa opioid receptor agonists
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
WO2014105655A1 (en) 2012-12-24 2014-07-03 Neurogastrx, Inc. Methods for treating gi tract disorders
US9844554B2 (en) 2014-06-24 2017-12-19 Neurogastrx, Inc. Prodrugs of metopimazine
JP6410641B2 (ja) 2015-03-04 2018-10-24 ローム株式会社 ワイヤレス送電装置、異物検出方法、充電器
US11246905B2 (en) 2016-08-15 2022-02-15 President And Fellows Of Harvard College Treating infections using IdsD from Proteus mirabilis
EP3558300B1 (en) 2016-12-21 2021-11-24 Tioga Pharmaceuticals, Inc. Solid pharmaceutical formulations of asimadoline
WO2019122361A1 (en) 2017-12-22 2019-06-27 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Asimadoline for use in treating pulmonary diseases, vascular diseases, and sepsis
MX2021000908A (es) 2018-07-23 2021-06-08 Trevi Therapeutics Inc Tratamiento de la tos cronica, la dificultad respiratoria y la disnea.
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
EP3932390A1 (en) 2020-07-02 2022-01-05 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical gel formulation containing asimadoline
WO2022085736A1 (ja) * 2020-10-20 2022-04-28 協和化学工業株式会社 診療支援装置、診療支援方法及び診療支援プログラム
WO2022155332A1 (en) * 2021-01-13 2022-07-21 Blue Therapeutics, Inc. Methods of treating irritable bowel syndrome

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4192883A (en) * 1976-04-09 1980-03-11 Pierre Fabre, S.A. Amides of pyrrolidinoethylamine which can be used in lung therapy
FR2421891A1 (fr) 1977-10-17 1979-11-02 Fabre Sa Pierre Obtention industrielle d'amides de la pyrrolidine ethyl amine
US4663343A (en) * 1985-07-19 1987-05-05 Warner-Lambert Company Substituted naphthalenyloxy-1,2-diaminocyclohexyl amide compounds
US4889860A (en) * 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4760069A (en) * 1985-09-23 1988-07-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
GB8601796D0 (en) * 1986-01-24 1986-02-26 Zambeletti Spa L Compounds
JPH02138254A (ja) 1988-02-23 1990-05-28 Glaxo Group Ltd 複素環誘導体
DE4034785A1 (de) 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
DE3935371A1 (de) 1988-12-23 1990-07-05 Merck Patent Gmbh Stickstoffhaltige ringverbindungen
US5232978A (en) * 1988-12-23 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung 1-(2-arylethyl)-pyrrolidines
US5389686A (en) * 1989-02-20 1995-02-14 Jouveinal Sa Analgesic properties of fedotozine
DE3916663A1 (de) * 1989-05-23 1990-11-29 Bayer Ag Substituierte (chinolin-2-yl-methoxy)phenyl-acyl-sulfonamide und -cyanamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US5232266A (en) * 1989-07-24 1993-08-03 Mork William J Upholstered article of furniture with interchangeable seating module
GB8926560D0 (en) 1989-11-24 1990-01-17 Zambeletti Spa L Pharmaceuticals
US5322848A (en) 1989-11-24 1994-06-21 Dr. Lo Zembeletti S.P.A. N-acyl-substituted azacyclic compounds, processes for their preparation, and their use as pharmaceuticals
US5300687A (en) 1991-07-18 1994-04-05 Ortho Pharmaceutical Corporation Trifluoromethylbenzylphosphonates useful in treating osteoporosis
DE4215213A1 (de) 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide
DE4425071C2 (de) * 1994-07-15 1996-08-29 Degussa Verfahren zur Herstellung optisch aktiver Pyrrolidine mit hoher Enantiomerenreinheit
DE19523502A1 (de) 1995-06-28 1997-01-02 Merck Patent Gmbh Kappa-Opiatagonisten für entzündliche Darmerkrankungen
DE19531464A1 (de) 1995-08-26 1997-02-27 Merck Patent Gmbh N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid
EP1021204B1 (en) * 1997-09-26 2005-12-28 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US20010051181A1 (en) * 1997-12-22 2001-12-13 Van Osdol William W. Novel formulations for the transdermal administration of asimadoline
DE19827633A1 (de) 1998-04-20 1999-10-21 Merck Patent Gmbh Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
AU754740B2 (en) * 1998-06-30 2002-11-21 Takeda Chemical Industries Ltd. Pharmaceutical composition for the treatment of diabetes
JP2000080047A (ja) 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
DE19849650A1 (de) * 1998-10-29 2000-05-04 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung des Irritable Bowel Syndroms (IBS)
ES2234523T3 (es) 1999-03-01 2005-07-01 Pfizer Products Inc. Acidos oxamicos que contienen ciano y sus derivados como ligandos de receptores tiroideos.
GB0015562D0 (en) 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
US20020025948A1 (en) * 2000-06-23 2002-02-28 Banks Bernard Joseph 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
US6846831B2 (en) * 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6262062B1 (en) 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6569449B1 (en) * 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
DE10116978A1 (de) 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
AU2002364517A1 (en) 2001-11-30 2003-06-17 Sepracor Inc. Tramadol analogs and uses thereof
JP2005531557A (ja) * 2002-05-17 2005-10-20 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 選択的オピエート受容体モジュレーターとして効果的な化合物の使用
JP2006502190A (ja) * 2002-09-18 2006-01-19 ザ キュレイターズ オブ ザ ユニバーシティー オブ ミズーリ デルタ−オピオイド受容体に選択的なオピエート類似物
DE10259245A1 (de) 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
PL2368553T3 (pl) * 2003-04-08 2015-05-29 Progenics Pharm Inc Preparaty farmaceutyczne zawierające metylonaltrekson
CA2521369A1 (en) 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
EP3342420A1 (en) * 2003-06-13 2018-07-04 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP2007509865A (ja) * 2003-10-30 2007-04-19 ティオガ ファーマシュウティカルズ，インコーポレイテッド 神経障害の治療における選択的オピエート受容体調節物質の使用
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
JP5416085B2 (ja) * 2007-03-30 2014-02-12 ティオガ ファーマシューティカルズ インコーポレイテッド 下痢型および交替型過敏性腸症候群の処置のためのカッパ−オピエートアゴニスト

Also Published As

Publication number Publication date
KR20120058614A (ko) 2012-06-07
JP2013173790A (ja) 2013-09-05
JP2010523492A (ja) 2010-07-15
RU2441655C2 (ru) 2012-02-10
AU2008232954A2 (en) 2011-12-01
US20110046174A1 (en) 2011-02-24
BRPI0809651A2 (pt) 2014-10-07
RU2009140042A (ru) 2011-05-10
SI2136801T1 (sl) 2013-01-31
WO2008121496A1 (en) 2008-10-09
PL2136801T3 (pl) 2013-01-31
CA2682608A1 (en) 2008-10-09
CN101677997B (zh) 2012-05-09
EP2136801B1 (en) 2012-08-29
AU2008232954A1 (en) 2008-10-09
EP2636407A2 (en) 2013-09-11
KR101263225B1 (ko) 2013-05-13
IL201226A0 (en) 2010-05-31
US20080242720A1 (en) 2008-10-02
MX2009010409A (es) 2010-03-29
CN102641265A (zh) 2012-08-22
EP2136801A1 (en) 2009-12-30
ES2393815T3 (es) 2012-12-28
EP2636407A3 (en) 2013-11-06
DK2136801T3 (da) 2012-12-17
HRP20120798T1 (hr) 2012-11-30
JP5416085B2 (ja) 2014-02-12
KR101208326B1 (ko) 2012-12-05
US8877800B2 (en) 2014-11-04
EP2561870A1 (en) 2013-02-27
EP2136801A4 (en) 2010-05-26
US7960429B2 (en) 2011-06-14
CY1113317T1 (el) 2016-04-13
CN101677997A (zh) 2010-03-24
PT2136801E (pt) 2012-12-06
KR20100016004A (ko) 2010-02-12

Similar Documents

Publication Publication Date Title
HK1139860A1 (en) Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome
EP2034844A4 (en) METHOD FOR THE TREATMENT OF DIARRHOID REIZDARM SYNDROME
EP2361089A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED FUNCTION OF -SYNUCLEINE
HK1143541A1 (en) Method for treatment of constipation-predominant irritable bowel syndrome
HK1165294A1 (zh) 用於治療假性延髓情緒及含嗎啡喃類化合物及抗抑鬱劑的組合
ZA201008491B (en) Detection of cannabis use
HK1221905A1 (zh) 作爲用於炎性腸病和/或腸易激綜合征的治療的應用
EP2249789A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF XEROSOMY
EP2276491A4 (en) NEW THERAPY FOR THE TREATMENT OF IRRITATION SYNDROME
EP2398921A4 (en) METHODS FOR THE DETECTION AND IDENTIFICATION OF BETA LACTAMASES WITH EXTENDED SPECTRUM
EP2488642A4 (en) COMPOSITIONS AND METHODS FOR TREATING THE MEDICINAL-INDUCED HAND-FOOT SYNDROME
IL200032A (en) Dopamine agonist for use in the treatment or prevention of endometriosis
BRPI1008259A2 (pt) composição para prevenção ou tratamento de síndrome do intestino irritável
IL204557A0 (en) Use of clec1b for the determination of cardiovascular and thrombotic risk
EP2285398A4 (en) METHOD AND COMPOSITIONS FOR TREATING ADIPOSITAS
IL210507A0 (en) Device for the thermal treatment of workpieces
SI2167085T1 (sl) 4-(2-(4-metilfenilsulfanil)fenil)piperidin za zdravljenje sindroma razdraĺ˝ljivega äśrevesja (ibs)
PL2588093T3 (pl) Tapentadol do zastosowania w leczeniu zespołu jelita drażliwego
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia
IL193686A0 (en) Agent for prevention/treatment of irritable bowel syndrome
EP2276502A4 (en) COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF NEUROLOGICAL INJURIES AND ASSOCIATED METHODS OF USE
ZA201003689B (en) Compositions and methods for the treatment of xerostomia
GB0705424D0 (en) Use of compounds in the treatment of pain and irritable bowel syndrome
GB0712390D0 (en) Use of compounds in the treatment of pain and irritable bowel syndrome
GB0809319D0 (en) The treatment of puritus

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170307